Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children - Full Text View

Sponsor:	Novartis Vaccines
Information provided by (Responsible Party):	Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier:	NCT00616421

Purpose

To evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY polysaccharide-protein conjugate vaccine.

Condition	Intervention	Phase
Meningococcal Infections	Biological: MenACWY-CRM Biological: Licensed meningococcal ACWY vaccine	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention
Official Title:	A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age

Resource links provided by NLM:

MedlinePlus related topics: Meningococcal Infections

Drug Information available for: Lactitol

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:

Number of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.

Seroresponse: For a subject with hSBA <1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.
Number of Subjects With hSBA Seroresponse, in Healthy Children 6 to 10 Years of Age [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.

Seroresponse: For a subject with hSBA <1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.

Secondary Outcome Measures:

Number Subjects With hSBA Seroresponse, in Healthy Children 2 to 10 Years of Age. [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.

Seroresponse: For a subject with hSBA <1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.
Number of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 10 Years of Age [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.

Seroresponse: For a subject with hSBA <1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.
Geometric Mean Titers (hSBA), in Healthy Children 2 to 10 Years of Age [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with hSBA (human Serum Bactericidal Activity) Geometric Mean Titers (GMTs) response against N. meningitidis serogroups A, C, W-135, and Y.
Number of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 5 and 6 to 10 Years of Age [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Geometric Mean Titers (hSBA), in Healthy Children 2 to 5 and 6 to 10 Years of Age [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of a single dose of the Novartis MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with hSBA (human Serum Bacterial Activity) Geometric Mean Titers (GMTs) response against N. meningitidis serogroups A, C, W-135, and Y.
Number of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age (2 Doses vs 1 Dose) [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of two doses of the Novartis MenACWY-CRM, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM, directed against N. meningitidis serogroups A, C, W-135, and Y.

Seroresponse: For a subject with hSBA <1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.
Number of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 5 Years of Age (2 Doses v/s 1 Dose) [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of two doses of the Novartis MenACWY-CRM, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM, directed against N. meningitidis serogroups A, C, W-135, and Y.

Seroresponse: For a subject with hSBA <1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.
Number of Subjects With hSBA GMTs, in Healthy Children 2 to 5 Years of Age (2 Doses v/s 1 Dose) [ Time Frame: 1 month postvaccination ] [ Designated as safety issue: No ]
The immunogenicity of two doses of the Novartis MenACWY-CRM vaccine, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM vaccine, in terms of hSBA (human Serum Bactericidal Activity) GMTs (Geometric Mean Titers) against N. meningitidis serogroups A, C, W-135, and Y.
Subjects With at Least One Reactogenicity Sign After Vaccination in Children 2 to 5 Years of Age [ Time Frame: Study days 1 to 7 ] [ Designated as safety issue: Yes ]
Safety was assessed in terms of the number of subjects with reported local and systemic reactions up to 7 days after each vaccination per vaccination group.
Subjects With at Least One Reactogenicity Sign After Vaccination in Children 6 to 10 Years of Age [ Time Frame: Study days 1 to 7 ] [ Designated as safety issue: Yes ]
Safety was assessed in terms of the number of subjects with reported local and systemic reactions up to 7 days after each vaccination per vaccination group.

Enrollment:	2907
Study Start Date:	March 2008
Study Completion Date:	October 2009
Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: MenACWY-CRM (1 dose) 1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.	Biological: MenACWY-CRM 1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly Other Name: Menveo
Active Comparator: Licensed polysaccharide vaccine 1 injection of a licensed meningococcal ACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1	Biological: Licensed meningococcal ACWY vaccine 1 injection of the licensed meningococcal ACWY was administered intramuscularly Other Name: Menactra
Experimental: MenACWY-CRM (2 doses) 2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.	Biological: MenACWY-CRM 2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age Other Name: Menveo

Eligibility

Ages Eligible for Study:	2 Years to 10 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy 2-10 years of age children, inclusive and for whom, after the nature of the study has been explained, the parent or legal guardian has provided written informed consent
who are available for all visits and telephone calls scheduled for the study
who are up-to-date with age-appropriate routine childhood vaccinations

Exclusion Criteria:

whose parent or legal guardian is unwilling or unable to give written informed consent
who had a previous or suspected disease caused by N. meningitidis;
who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)
who have received any investigational agents or vaccines within 90 days prior to enrollment
who have any serious acute, chronic or progressive disease
who have epilepsy or any progressive neurological disease or history of Guillain Barré Syndrome
who have a history of anaphylaxis, serious vaccine reactions
who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from
who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
who have Down's syndrome or other known cytogenic disorders

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00616421

Show 68 Study Locations

Sponsors and Collaborators

Novartis Vaccines

Investigators

Study Director:

Novartis Vaccines and Diagnostics

Novartis

More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010 Nov 23;28(50):7865-72. Epub 2010 Oct 29.

Responsible Party:	Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier:	NCT00616421 History of Changes
Other Study ID Numbers:	V59P20, 11278
Study First Received:	January 31, 2008
Results First Received:	February 28, 2011
Last Updated:	December 7, 2011
Health Authority:	United States: Food and Drug Administration; Canada: Health Canada

Keywords provided by Novartis:

vaccine
children
healthy
meningitis

meningococcal
prevention of meningococcal disease serogroups ACWY
Menveo

Additional relevant MeSH terms:

Meningococcal Infections
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Lactitol

Cathartics
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 12, 2012